Air Industries Group — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with FY2022. Air Industries Group manufactures precision aerospace and defense components and assemblies, with most sales tied to military aircraft programs and a small number of large prime contractors.
Financial performance and position
| Metric | FY2023 / year-end | FY2022 / comparison |
|---|---|---|
| Net sales | $51.516 million | $53.238 million; down 3.2% |
| Gross profit / margin | $7.428 million / 14.4% | $7.452 million / 14.0% |
| Operating loss | $295,000 | $194,000 |
| Net loss | $2.131 million; $0.65 per diluted share | $1.076 million; $0.33 per diluted share |
| Interest expense | $1.920 million; weighted average Current Credit Facility rate 7.55% | $1.338 million; rate 4.50% |
| Cash from operations | $4.862 million | $448,000 |
| Capital expenditures | $2.119 million | $2.361 million |
| Cash at year-end | $346,000 | $281,000 |
| Working capital | $12.117 million | $18.600 million |
| Total assets / stockholders’ equity | $50.715 million / $15.190 million | $53.814 million / $16.839 million |
Operating cash flow increased mainly because accounts receivable and inventory declined and customer deposits rose. Customer deposits were $3.557 million at year-end, versus $781,000 a year earlier. Inventory was $29.851 million, approximately 59% of total assets.
Third-party debt was $17.148 million at year-end, including $15.849 million under the Webster Bank facility; related-party notes totaled $6.162 million. Total indebtedness was reported at approximately $23.311 million, excluding lease liabilities. The bank facility is secured by substantially all company assets. Cash, substantial debt service needs, and covenant restrictions constrain liquidity.
Changes, outlook and material risks
- Sales declined due mainly to a supplier’s failure to deliver raw materials for a key program and changes in customer mix and production requirements. Gross margin improved modestly, but higher interest expense and operating costs contributed to a larger net loss.
- Bookings rose 55% to $62.262 million; book-to-bill was 1.20x, compared with 0.75x in 2022. Funded backlog was $98.3 million, up 14.7%, with most expected to ship within 24 months.
- Management expects FY2024 sales to increase, aims to reach profitability and improve the financial position, and plans approximately $2 million of FY2024 equipment investment. These are expectations, not guarantees.
- Management cites $191.9 million of total unfilled contract values in its outlook, while another section reports $191.1 million of potential sales under awarded contracts, including funded backlog. The filing does not reconcile these figures.
- Going concern and covenants: The company met its fixed-charge coverage covenant at December 31, 2023 (1.31x versus 0.95x required), but was out of compliance at March 31, 2024 (1.10x required). A waiver was uncertain as of the filing. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern if a waiver is not obtained or future covenants are missed. The company classified its term loan as current due to potential callability.
- Management says it began steps to refinance debt. The Webster facility matures December 30, 2025; related-party notes mature July 1, 2026. Refinancing could bring higher rates, tighter covenants or dilution. Revolver borrowing capacity was reported at approximately $9.830 million, subject to facility terms and availability.
- Key operating exposures include concentrated customers and programs, fixed-price contracts, dependence on sole-source suppliers, raw-material and skilled-labor costs, production delays, and reliance on U.S. defense spending. Four customers represented 64.2% of FY2023 sales; military products generated 82.3% of sales.
- Management found disclosure controls and internal control over financial reporting ineffective at December 31, 2023, citing an unremediated material weakness in IT access/change controls and segregation of duties. Effectiveness testing was ongoing.
- A pending Contract Pharmacal dispute seeks up to $700,000 after the court rejected key motions by the claimant; the company disputes the claim. Management says it knows of no proceedings expected to have a material adverse effect.
Investor verification priorities
- Check whether the lender granted a waiver for the March 31, 2024 covenant breach, subsequent covenant compliance, and any changes to borrowing access or debt classification.
- Reconcile the disclosed $191.9 million and $191.1 million contract-value figures; assess the funded backlog’s shipment timing, conversion and cancellation risks.
- Review cash generation quality, working-capital needs, inventory valuation and customer-deposit obligations, given low cash and inventory’s large share of assets.
- Track refinancing terms and maturities for bank debt and related-party notes, including interest costs, collateral, covenants and potential dilution.
- Monitor remediation and testing of the internal-control material weakness, as well as the outcome and accounting treatment of the Contract Pharmacal litigation.